“Objective: There is currently no effective medicine or supplement for clearance of high risk- human papillomavirus (HR-HPV) infections. We have taken a systematic approach evaluating the potential use of AHCC supplementation to support clearance of HR-HPV infections. The primary objective of this research was to evaluate AHCC supplementation to modulation of the host immune system to clear HR-HPV infections from bench to bedside.
Methods: Cervical cancer cells, CaSki (HPV16+), HeLa(HPV18+), SiHa(HPV16/18+), and C-33A(HPV−), were treated in vitro with AHCC 0.42 mg/mL daily x7 days then observed x7 days with daily sample collection.
Tumors were evaluated for HR-HPV expression by PCR. Two pilot studies of 10 patients each were conducted in women with confirmed persistent HR-HPV+ infections. The 1st study evaluated AHCC 3g from 5 weeks up to 6 months and 2nd study evaluated AHCC 1g < 8 months. HR-HPV DNA status and the immune panel were monitored at each visit.
Results: HR-HPV clearance was observed in vitro and confirmed in the animal studies as a durable response. Four of six (66.7%) patients had confirmed HR-HPV clearance after 3–6 months of AHCC 3g. Similarly, 4 of 9 (44%) patients had confirmed HR-HPV clearance after 7 months of AHCC 1g. Suppression of IFNβ <25 pg/mL was observed in those clearing the HR-HPV infection.
Conclusion: Pre-clinical in vitro and in vivo studies demonstrated durable clearance of HR-HPV infections. The preliminary data from the two pilot studies suggested that AHCC supplementation supports the host immune system for successful clearance of HR-HPV infections. A confirmatory phase II randomized, double-blinded, placebo-controlled study is ongoing.
“It’s a potential breakthrough in treating the currently untreatable human papilloma virus (HPV) — one that comes directly from nature.
At a recent Society for Integrative Oncology conference, Judith A. Smith, a pharmacist and an associate professor at the University of Texas Health Science Center at Houston Medical School, presented the results of a small study that found the supplement active hexose correlated compound (AHCC) can eliminate the HPV virus.
The nutritional supplement is made from Japanese mushrooms.
Smith noted that HPV is linked to 99 percent of cervical cancers cases, as well as cases of many other potentially fatal cancers. As it stands, there are no medications or supplements that can effectively treat HPV.
“Patients who learn that they have HPV, and their doctors, are understandably frustrated because all we can do is monitor them for the abnormal changes associated with cancer. What we need is a safe, effective treatment for HPV before the cancer occurs,” Smith said in a press statement…”
I’ve often said that if chemotherapy didn’t have negative side effects, cancer would not be the health hazard it is today. As a long-term cancer survivor who lives with a number of long-term and late-stage side effects I am ecstatic to find research documenting non-toxic therapies that can eliminate cancer causing virus’ as well as integrate with conventional chemotherapy regimens.
According to the studies linked and excerpted below AHCC can not only cure Human papillomaviruses (HPV) but it can reduce chemotherapy toxicities as well as enhance the efficacy of cisplatin, and 5-FU and improving the immune systems of cancer patients.
I take Now AHCC Extra Strength capsules. One daily with food.
“Active hexose correlated compound (AHCC) is a widely sold health supplement extracted from Basidiomycete mushrooms (eg, shiitake [Lentinula edodes]) that is purported to improve immune function.
AHCC has been evaluated in in vitro, in vivo, and in-human studies because of its antioxidant and immune-enhancing effects. Most in-human studies have evaluated its effect on reducing toxicities associated with anticancer treatments…
Several studies also evaluated AHCC in combination with other anticancer therapies. A study of BALB/cA mice demonstrated that AHCC enhanced the efficacy of cisplatin, resulting in smaller tumors compared with mice that received cisplatin only.…
A breast cancer mouse model found that AHCC did not affect tamoxifen or letrozole efficacy, but had some cytotoxic effect on its own.4 In this study, AHCC also increased food intake, improved blood urea nitrogen and serum creatinine levels, and reduced bone marrow suppression. Another study showed that AHCC reduced myelosuppression and reversed liver injury associated with 5-fluorouracil treatment...
Though most other studies evaluated the effect of AHCC on toxicities caused by anticancer treatment, 2 studies investigated the effect of AHCC on liver cancer outcomes. A prospective cohort study of 269 patients with hepatocellular carcinoma (HCC) who underwent liver resection demonstrated that AHCC administration after surgery resulted in a longer time to recurrence and increased overall survival compared with those who did not receive AHCC.…
Several studies showed that AHCC reduced toxicities associated with anticancer treatment. A retrospective review of 41 women with breast cancer receiving anthracyclines and taxanes found that AHCC reduced the number of neutrophil-related events and the need for granulocyte colony–stimulating factor…
A study of 75 patients with pancreatic cancer receiving gemcitabine demonstrated that 6 g of AHCC for 2 months resulted in significantly fewer grade 3 adverse events (17% vs 53%; P = .0005) and fewer taste disorders (17% vs 56%; P = .0007) compared with patients who did not take AHCC.13
Animal studies suggest that AHCC may have anticancer and immune-enhancing properties. In-human studies suggest that AHCC is well-tolerated and may reduce the incidence of adverse effects among patients receiving chemotherapy…”